• Tetrazolium (chloride): Advancing Translational Mitochondria

  2026-07-10

  This thought-leadership article explores the mechanistic foundations and translational impact of Tetrazolium (chloride) as a precision redox indicator for mitochondrial and cell viability assays in ischemic injury research. By integrating recent mechanistic discoveries—such as NRF2 pathway modulation in cerebral ischemia—with strategic guidance for experimental design, we provide a roadmap for researchers seeking robust, clinically meaningful endpoints and assay optimization. The discussion highlights competitive assay technologies, protocol recommendations, and future directions for cross-disciplinary innovation, with reference to both recent literature and APExBIO’s industry-leading Tetrazolium (chloride) reagent.

• SP600125 for High-Fidelity JNK Pathway Interrogation in Adva

  2026-07-09

  Explore the nuanced use of SP600125, a potent JNK inhibitor, for dissecting cytokine regulation and translational control in apoptosis and cancer research. This article uniquely bridges chemoproteomic insights with practical assay design, offering advanced strategies beyond standard MAPK inhibition.

• KX2-391 Dihydrochloride: Protocols for Dual Src & Tubulin In

  2026-07-09

  KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) empowers researchers with a dual-action approach for targeted oncology, antiviral, and neurotoxin studies. This article translates recent breakthroughs into stepwise protocols, actionable troubleshooting, and comparative insights to maximize experimental success.

• Dasatinib Monohydrate: Advanced Workflows for Tumor Assemblo

  2026-07-08

  Dasatinib Monohydrate (BMS-354825) is redefining translational cancer research by enabling robust kinase inhibition in complex tumor microenvironment models. This guide details practical protocol enhancements and troubleshooting strategies for leveraging Dasatinib in assembloids and organoid systems, supporting the next wave of personalized therapy design.

• RIPA Lysis Buffer (Strong): Precision Protein Extraction for

  2026-07-08

  RIPA Lysis Buffer (Strong) by APExBIO offers unmatched efficiency for extracting high-quality proteins from complex animal tissues, supporting demanding applications like blood-brain barrier research and neuroinflammation studies. Its robust formulation, optimized for Western blot and immunoprecipitation, delivers reproducible results even with challenging CNS samples.

• Nilotinib (AMN-107): Potent BCR-ABL Inhibitor for CML Resear

  2026-07-07

  Nilotinib (AMN-107) is a selective, orally bioavailable tyrosine kinase inhibitor with nanomolar potency against wild-type and mutant BCR-ABL, making it a benchmark tool in chronic myeloid leukemia research. Its efficacy extends to KIT and PDGFR kinases, and its physicochemical profile supports robust in vitro and in vivo applications. This article provides an evidence-based evaluation of its mechanism, use cases, and protocol parameters.

• CD28-ARS2 Axis and PKM Splicing Drive CD8+ T Cell Flexibilit

  2026-07-07

  This article examines how the CD28-ARS2 signaling axis enables metabolic flexibility in CD8+ T cells via alternative splicing of pyruvate kinase M (PKM), as reported by Holling et al. The findings elucidate a new post-transcriptional mechanism supporting antitumor immunity and offer insight into how metabolic reprogramming can be leveraged in immunotherapy research.

• TBXA2R–ERM Axis Drives Motility and Metastasis in TNBC Cells

  2026-07-06

  Leguay et al. identify TBXA2R as a key activator of ezrin, radixin, and moesin (ERM) proteins, crucially linking GPCR signaling to cytoskeletal remodeling in triple-negative breast cancer (TNBC). This mechanistic insight reveals new intervention points for metastatic progression and offers direction for future kinase-targeted cancer research.

• EZH2 Inhibition and 5-Azacytidine Synergy in PTEN-Deficient

  2026-07-06

  This study reveals that while 5-Azacytidine alone is insufficient to overcome immune evasion in PTEN-deficient glioblastoma, its combination with EZH2 inhibition restores type I interferon responses by reactivating viral mimicry. These findings provide a mechanistic rationale for epigenetic combination therapies to enhance antitumor immunity in otherwise resistant GBM subtypes.

• Griseofulvin: Microtubule Associated Inhibitor for Antifunga

  2026-07-05

  Griseofulvin stands out as a high-purity microtubule associated inhibitor, facilitating robust antifungal drug research and mechanistic studies of mitosis. Its DMSO solubility and validated mechanism enable reproducible, high-content workflows, empowering researchers to dissect microtubule dynamics and optimize fungal cell mitosis inhibition.

• Caspase-3/7 Inhibitor I: Precision in Apoptosis Dissection W

  2026-07-04

  Caspase-3/7 Inhibitor I empowers researchers to selectively and reversibly inhibit key apoptotic pathways, supporting high-fidelity mechanistic studies in cell models. Its potency and specificity make it indispensable for dissecting caspase signaling in contexts like cancer research or infection-triggered cell death.

• AP-1 Inhibition Drives Ferroptosis in Myeloma via PI3K/AKT B

  2026-07-03

  The referenced study demonstrates that T-5224, a selective C-Fos/AP-1 inhibitor, induces ferroptosis in multiple myeloma cells by suppressing the PI3K/AKT signaling pathway. These findings reveal a mechanistic link between AP-1 inhibition and ferroptosis, offering new therapeutic strategies for multiple myeloma and deepening understanding of cell death regulation in hematological malignancies.

• Catalpol’s Mechanisms in Alzheimer’s Disease: Anti-Inflammat

  2026-07-03

  This review dissects the multifaceted mechanisms by which catalpol, an iridoid glycoside from Rehmannia glutinosa, exerts neuroprotective effects in Alzheimer’s disease (AD) models. The reference study highlights catalpol’s antioxidant, anti-inflammatory, and antiapoptotic actions, providing a foundation for future translational research.

• O-GlcNAcylation and Galectin-3 in Extraembryonic Endoderm Fa

  2026-07-02

  This study delineates the role of O-GlcNAcylation and galectin-3 in the differentiation of mouse embryonic stem cells (mESCs) toward the extraembryonic endoderm (XEN) lineage. The findings reveal that decreased global O-GlcNAcylation and altered galectin-3 secretion accompany XEN differentiation, but inhibiting O-GlcNAc cycling alone does not block lineage commitment. These insights refine our understanding of pluripotency regulation and post-translational control during early development.

• FH1 (Catalog No. B3700): Reliable Hepatocyte Maturation for

  2026-07-02

  Explore the laboratory impact of FH1 (Catalog No. B3700) for enhancing hepatocyte functionality and reproducibility in iPS-derived liver cell assays. This article guides researchers through scenario-driven questions, protocol optimization, and vendor reliability, ensuring evidence-backed decisions for cell-based workflows using SKU B3700.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page